Zydus receives EIR from USFDA for its injectables manufacturing facility at Jarod

Ahmedabad, India, 27 May, 2022

Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), an innovation driven global lifesciences company announced that it has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Jarod injectables manufacturing facility near Vadodara, India. Zydus said that the USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI) and has concluded that the inspection is considered as "closed" under 21 CFR 20.64(d)(3). The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs. The USFDA had inspected the facility from 24th February to 10th March, 2022.

About Zydus

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. For more details visit www.zyduslife.com.

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878